Gavilimomab
[A murine IgM monoclonal antibody (MoAb) developed for the potential treatment of graft versus host disease (GvHD). MoAb ABX-CBL recognizes human CD147 antigen, weakly expressed on human leukocytes and up-regulated on activated lymphocytes. This MoAb is capable of neutralizing inflammatory reactions via a complement-dependent cytotoxic mechanism. However, MoAb ABX-CBL does not offer an improvement over antithymocyte globulin in the treatment of acute steroid resistant GVHD. ( NCI )]
UMLS (NCI) C0935795Monoclonal Antibody ABX-CBL
- Amino Acid, Peptide, or Protein
- Pharmacologic Substance
- Immunologic Factor
Buy website
Medical Clinic. Optician. Pharmacy. Physician. Travel Agency. Hotel reservation. Child Care. Education. Teachers. Lessons. Tests and Exams. Certification. Shopping Center. Store. Real Estate.Affordable prices from $100.
  |
home
